SCHEMBL3483717

SCHEMBL3483717

CCC(=O)c1ccc(OC)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.49
RAB9A P51151 4/20 0.49
HTT P42858 2/20 0.47
HPGD P15428 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPK1 P28482 1/20 0.47
THRA P10827 1/20 0.47
THRB P10828 1/20 0.47
HMGCR P04035 1/20 0.46
GSK3B P49841 1/20 0.44
HSP90AB1 P08238 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5729791 0.86 CYP2C19 (0.55) NPC1RAB9AHTTHPGDALDH1A1
SCHEMBL27669562 0.86 KDM4E (0.55) NPC1HPGDALDH1A1THRATHRB
SCHEMBL5051445 0.86 GSK3B (0.58) NPC1RAB9AHTTHPGDALDH1A1
SCHEMBL31098753 0.85 THRA (0.48) ALDH1A1THRATHRBHMGCRHSP90AB1
SCHEMBL27688365 0.84 THRA (0.53) THRATHRBHMGCRHSP90AB1MAPT
SCHEMBL28800858 0.83 THRA (0.66) THRATHRBSMN1; SMN2
SCHEMBL27831620 0.83 THRA (0.43) RAB9AHTTALDH1A1THRATHRB
SCHEMBL27719541 0.82 THRB (0.45) NPC1RAB9AALDH1A1THRATHRB
SCHEMBL27811253 0.82 MTNR1A (0.48) NPC1RAB9AHTTHPGDTHRA
SCHEMBL5914630 0.82 SMN1; SMN2 (0.63) NPC1RAB9AHTTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105541738-B A kind of preparation method of the acetophenone compounds of triazole substitution 西北师范大学 2018-04-06 CN disclosed
CN-105229009-B 2-phenylimidazo [1,2-A ] pyrimidines as imaging agents 豪夫迈·罗氏有限公司 2017-09-29 CN disclosed
CN-103221047-A Compounds and methods TEMPERO PHARMACEUTICALS INC 2013-07-24 CN disclosed
CN-102670617-B Application of ibuprofen 2-(2-arylmorpholine-4-yl) ethyl ester in preparation of antidepressant drugs UNIV HUNAN 2013-03-20 CN disclosed
CN-102670617-A Application of ibuprofen 2-(2-arylmorpholine-4-yl) ethyl ester in preparation of antidepressant drugs UNIV HUNAN 2012-09-19 CN disclosed
CN-101636155-A Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBOTT LAB 2010-01-27 CN disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
CN-101522192-A Substituted imidazolone derivatives, preparation and uses GENFIT (FR) 2009-09-02 CN disclosed
US-20090062236-A1 Programmable genotoxic agents and uses therefor MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-03-05 US disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed
US-7169611-B2 Programmable genotoxic agents and uses therefor MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-01-30 US disclosed
EP-0758249-B1 PROGRAMMABLE GENOTOXIC AGENTS AND USES THEREFOR MASSACHUSETTS INST TECHNOLOGY (US) 2006-08-02 EP disclosed
US-20030220311-A1 Programmable genotoxic agents and uses therefor MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2003-11-27 US disclosed
US-6500669-B1 FOR SELECTIVELY KILLING A SUBPOPULATION OF CELLS IN A HETEROGENOUS CELL POPULATION; ALKYLATING AGENTS OR HEAVY METAL COORDINATION COMPOUNDS LINKED TO A COMPOUND THAT BINDS TO STEROID RECEPTOR MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2002-12-31 US disclosed
US-5879917-A DESIGNED TO KILL SELECTED CELLS PRESENT IN HETERGENOUS CELL POPULATION; CAUSE SELECTIVE KILLING OF TRANSFORMED CELLS, VIRAL-INFECTED CELLS, ETC. MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1999-03-09 US disclosed
EP-0758249-A1 PROGRAMMABLE GENOTOXIC AGENTS AND USES THEREFOR MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1997-02-19 EP disclosed
WO-1995030442-A1 PROGRAMMABLE GENOTOXIC AGENTS AND USES THEREFOR MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1995-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES IPO5, PPIP5K2, IPO4 NPC1 1123/4885RAB9A 1905/4885HTT 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.